|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Reaction synthesis of Ni-Al-based particle composite coatings 显示文摘 | SUSAN D F MISIOLEK W Z MARDER A R | 2001 | Metall Mater Trans2001，32，： | 1 |
| 2 | Mutations in filamin 1 Prevent Migration of Cerebral Cortical Neurons in Human Periventricular Heterotopia显示文摘 | Jeremy W Fox Edward D Lamperti Yaman Z Ek?io?lu Susan E Hong Yuanyi Feng Donna A Graham Ingrid E Scheffer William B Dobyns Betsy A Hirsch Rodney A Radtke Samuel F Berkovic Peter R Huttenlocher Christopher A Walsh | 1998 | Neuron1998，，6： | 1 |
| 3 | Activation of insulin-reactive CD8 T-cells for development of autoim-mune diabetes 显示文摘 | SUSAN F W KHAI S L GWEN S | 2009 | Diabetes2009，58，5： | 1 |
| 4 | Clinical measurement of sit-to-stand performance in people with balance disorders: Validity of data for the five-times-sit-to-stand test 显示文摘 | Susan L W Dina M W Gregory F M | 2005 | Physical Therapy2005，85，11： | 1 |
| 5 | Reaction synthesis of Ni-Al-hased particle composite 显示文摘 | Susan D F Misiolek W Z Marder A R | 2001 | Metall Mater Trans A2001，32，： | 1 |
| 6 | The mean structure of the Mindanao current at 8°N 显示文摘 | SUSAN W ERIC F JOHN T | 1995 | Journal of Geophysical Research1995，9，18： | 1 |
| 7 | Development of an enzyme - linked immunosorbent assay for alachlor and its application to the analysis of environmental water samples 显示文摘 | Paul C C F Stephen J W Susan R H | 1990 | J Agric Food Chem1990，38，1： | 1 |
| 8 | CC4-03: The Use of Administrative Data and Natural Language Processing to Estimate the Incidence of Statin-related Rhabdomyolysis显示文摘 | James F Susan H Noel W | 2012 | Clin Med Res2012，10，8： | 1 |
| 9 | Contemporaneous fluctuations in T cell responses to persistent herpes virus infections显示文摘 | Tania C Chrysa F Susan W | 2005 | Eur J Immunol2005，35，： | 1 |
| 10 | Rational de- sign of α-Helical antimicrobial peptides with enhanced activities and specificity/therapeutic index显示文摘 | Yuxin Chen Colin T M Susan W F | 2005 | J Biol Chem2005，280，12： | 1 |
| 11 | Hypoxia increases thrombospondin-1 transcript and protein in cultured endothelial cells 显示文摘 | MICHAEL W P LORA W F SUSAN P P | 1998 | J Lab Clin Med1998，132，6： | 1 |
| 12 | Reaction synthesis of Ni-Al-based particle composite coatings显示文摘 | Misiolek W Z Mader A R | 2001 | Metallurgical and Materiala Transactions A2001，32，： | 1 |
| 13 | Indexing by Latent Semantic Analysis 显示文摘 | SCOTT D SUSAN T D GEORGE W F | 1990 | Journal of the American Society for Information Science1990，41，6： | 1 |
| 14 | Reaction synthesis of Ni-Al-based particle composite coatings 显示文摘 | Susan D F Misiolek W Z Marder A R | 2001 | Metallurgical and Materials Transactions A2001，32，2： | 1 |
| 15 | P/M titanium matrix composite: From war to fun & games显示文摘 | SUSAN M A PAUL F W | 1996 | Science and Technology1996，，： | 1 |
| 16 | Comparisons of Causes of Death and Mortality Rates Among HIV-Infected Persons: Analysis of the Pre-, Early, and Late HAART (Highly Active Antiretroviral Therapy) Eras显示文摘 | Nancy F Crum Robert H Riffenburgh Scott Wegner Brian K Agan Sybil A Tasker Katherine M Spooner Adam W Armstrong Susan Fraser Mark R Wallace | 2006 | JAIDS Journal of Acquired Immune Deficiency Syndromes2006，，2： | 1 |
| 17 | Competing risks of death in younger and older postmenopausal breast cancer patients显示文摘AIM: To show a new paradigm of simultaneously testing whether breast cancer therapies impact other causes of death. METHODS: MA.14 allocated 667 postmenopausal women to 5 years of tamoxifen 20 mg/daily ± 2 years of octreotide 90 mg, given by depot intramuscular injections monthly. Event-free survival was the primary endpoint of MA.14; at median 7.9 years, the tamoxifen+octreotide and tamoxifen arms had similar event-free survival(P = 0.62). Overall survival was a secondary endpoint, and the two trial arms also had similar overall survival(P = 0.86). We used the median 9.8 years follow-up to examine by intention-to-treat, the multivariate time-to-breast cancer-specific(Br Ca) and other cause(OC) mortality with log-normal survival analysis adjusted by treatment and stratification factors. We tested whether baseline factors including Insulin-like growth factor 1(IGF1), IGF binding protein-3, C-peptide, body mass index, and 25-OH vitamin D were associated with(1) all cause mortality, and if so; and(2) cause-specific mortality. We also fit step-wise forward cause-specific adjusted models.RESULTS: The analyses were performed on 329 patients allocated tamoxifen and 329 allocated tamoxifen+octreotide. The median age of MA.14 patients was 60.1 years: 447(82%) < 70 years and 120(18%) ≥ 70 years. There were 170 deaths: 106(62.3%) BrC a; 55(32.4%) OC, of which 24 were other malignancies, 31 other causes of death; 9(5.3%) patients with unknown cause of death were excluded from competing risk assessments. BrC a and OC deaths were not significantly different by treatment arm(P = 0.40): tamoxifen patients experienced 50 BrC a and 32 OC deaths, while tamoxifen + octreotide patients experienced 56 Br Ca and 23 OC deaths. Proportionately more deaths(P = 0.004) were from BrC a for patients< 70 years, where 70% of deaths were due to Br Ca, compared to 54% for those ≥ 70 years of age. The proportion of deaths from OC increased with increasing body mass index(BMI)(P = 0.02). Higher pathologic T and N were associated with more BrC a deaths(P < 0.0001 and 0.002, respectively). The cumulative hazard plot for Br Ca and OC mortality indicated the concurrent accrual of both types of death throughout followup, that is the existence of competing risks of mortality. MA.14 therapy did not impact mortality(P = 0.77). Three baseline patient and tumor characteristics were differentially associated with cause of death: older patients experienced more OC(P = 0.01) mortality; patients with T1 tumors and hormone receptor positive tumors had less BrC a mortality(respectively, P = 0.01, P = 0.06). Additionally, step-wise cause-specific models indicated that patients with node negative disease experienced less BrC a mortality(P = 0.002); there was weak evidence that, lower C-peptide(P = 0.08) was associated with less BrC a mortality, while higher BMI(P = 0.01) was associated with worse OC mortality.CONCLUSION: We demonstrate here a new paradigm of simultaneous testing of therapeutics directed at multiple diseases for which postmenopausal women are concurrently at risk. Octreotide LAR did not significantly impact breast cancer or other cause mortality, although different baseline factors influenced type of death. | Judy-Anne W Chapman Kathleen I Pritchard Paul E Goss James N Ingle Hyman B Muss Susan F Dent Ted A Vandenberg Brian Findlay Karen A Gelmon Carolyn F Wilson Lois E Shepherd Michael N Pollak | 2014 | World Journal of Clinical Oncology2014，5，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员